The tutorial series combines the Processing Foundation's 20+ year legacy of making programming accessible to artists with the Tezos Foundation's commitment to fostering digital art innovation on the ...

Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Dr. Allen Davidoff, Chief Executive Officer of XORTX, ...

NEW YORK, Oct. 14, 2025 /PRNewswire/ -- The Processing Foundation and Tezos Foundation today announced a strategic partnership to introduce an educational series showcasing p5.js 2.0, the latest ...

DILG-7 Regional Director Leocadio Trovela (3rd from right) urges the Bohol provincial government to sustain the halfway house ...

CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

(MENAFN- GlobeNewsWire - Nasdaq) Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Dr. Allen Davidoff, ...

CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company ...

Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Dr. Allen Davidoff, Chief Executive Officer of XORTX, ...

Investing.com -- XORTX Therapeutics Inc (NASDAQ:XRTX) stock surged 40% in premarket trading Friday after the company announced it has entered into a binding term sheet to acquire a Renal Anti-Fibrotic ...